Spots Global Cancer Trial Database for cyclophosphamide
Every month we try and update this database with for cyclophosphamide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | NCT02414269 | Malignant Pleur... Mesothelioma Metastases Lung Cancer Breast Cancer | iCasp9M28z T ce... cyclophosphamid... pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Pyrotinib in Combination With Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II Trial | NCT04872985 | Breast Cancer Hormone-recepto... | Pyrotinib Epirubicin Doxorubicin Hyd... Cyclophosphamid... Docetaxel Nab paclitaxel Placebo | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan | NCT02030964 | Neuroblastoma | DFMO Celecoxib Cyclophosphamid... Topotecan | 2 Years - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | NCT04007029 | CD19 Positive CD20 Positive Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Prima... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Mant... Refractory Prim... Refractory Smal... | Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Tocilizumab | 18 Years - 70 Years | Jonsson Comprehensive Cancer Center | |
| Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma | NCT00005959 | Lymphoma | filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... | 18 Years - | National Cancer Institute (NCI) | |
| Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP) | NCT00450385 | Lymphoma | Rituximab Cyclophosphamid... Doxorubicin Prednisone Vincristine | 18 Years - 120 Years | University of Miami | |
| Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies | NCT01175785 | Accelerated Pha... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Phase C... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Myelo... | umbilical cord ... fludarabine pho... cyclophosphamid... ex vivo-expande... total-body irra... cyclosporine mycophenolate m... laboratory biom... | 6 Months - 45 Years | Nohla Therapeutics, Inc. | |
| Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer | NCT00004135 | Kidney Cancer Melanoma (Skin) | filgrastim therapeutic all... cyclophosphamid... fludarabine pho... peripheral bloo... | 18 Years - 65 Years | University of Chicago | |
| Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma | NCT00736450 | Contiguous Stag... Noncontiguous S... Stage I Adult D... Stage III Adult... Stage IV Adult ... | oblimersen sodi... rituximab cyclophosphamid... doxorubicin hyd... vincristine sul... prednisone biopsy microarray anal... immunohistochem... gene expression... cytogenetic ana... | 19 Years - | University of Nebraska | |
| Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma | NCT02567435 | Alveolar Rhabdo... Botryoid-Type E... Embryonal Rhabd... Rhabdomyosarcom... Sclerosing Rhab... Spindle Cell Rh... | Cyclophosphamid... Dactinomycin Irinotecan Hydr... Laboratory Biom... Questionnaire A... Radiation Thera... Temsirolimus Vincristine Sul... Vinorelbine | - 40 Years | National Cancer Institute (NCI) | |
| Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia | NCT00453388 | Acute Myeloid L... de Novo Myelody... Fanconi Anemia Previously Trea... | Allogeneic Bone... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Nonmyeloablativ... Total-Body Irra... | - | Fred Hutchinson Cancer Center | |
| S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer | NCT00068601 | Breast Cancer Infertility Menopausal Symp... | cyclophosphamid... goserelin aceta... | 18 Years - 49 Years | SWOG Cancer Research Network | |
| Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma | NCT00055640 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... microarray anal... | 18 Years - | Case Comprehensive Cancer Center | |
| Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy | NCT02139280 | Hematologic Mal... | Cyclophosphamid... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | NCT02877303 | B Acute Lymphob... B Lymphoblastic... | Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul... | 14 Years - | M.D. Anderson Cancer Center | |
| Phase II Trial for Large ER-Negative Breast Cancers | NCT01869192 | Malignant Neopl... | Epirubicin Cyclophosphamid... Docetaxel Capecitabine Radiation Thera... | 18 Years - | University of Colorado, Denver | |
| Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer | NCT00003927 | Breast Cancer | filgrastim amifostine trih... cyclophosphamid... doxorubicin hyd... paclitaxel peripheral bloo... | 18 Years - 59 Years | City of Hope Medical Center | |
| Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas | NCT02451982 | Pancreatic Canc... | Cyclophosphamid... GVAX pancreatic... Nivolumab Urelumab BMS-986253 | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma | NCT00070083 | Lymphoma | oblimersen sodi... rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... | 19 Years - | National Cancer Institute (NCI) | |
| Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer | NCT01855828 | Her2-Positive B... | Pertuzumab Trastuzumab Paclitaxel 5-fluorouracil Epirubicin Cyclophosphamid... | 18 Years - 65 Years | Yale University | |
| Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma | NCT00101010 | Lymphoma | Filgrastim Pegfilgrastim Rituximab Cyclophosphamid... Pegylated lipos... Prednisone Vincristine Sul... | 61 Years - | M.D. Anderson Cancer Center | |
| Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients | NCT02204241 | Multiple Myelom... | Carfilzomib Cyclophosphamid... Dexamethasone | 65 Years - | Stichting European Myeloma Network | |
| A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only | NCT00451178 | Lymphoma | enzastaurin rituximab cyclophosphamid... doxorubicin vincristine prednisone | 18 Years - | Eli Lilly and Company | |
| Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors | NCT05755854 | Hematologic Dis... | allogeneic γ9δ2... Fludarabine Cyclophosphamid... Zoredronic acid | 12 Years - 65 Years | Anhui Provincial Hospital | |
| Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia | NCT00003868 | Leukemia | cyclophosphamid... methotrexate allogeneic bone... peripheral bloo... iodine I 131 mo... radiation thera... | 2 Years - 55 Years | Fred Hutchinson Cancer Center | |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia | NCT00002549 | Leukemia | filgrastim busulfan cyclophosphamid... cytarabine daunorubicin hy... etoposide idarubicin mesna mitoxantrone hy... allogeneic bone... autologous bone... peripheral bloo... radiation thera... | 15 Years - 60 Years | National Cancer Institute (NCI) | |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | NCT03842696 | Hematologic Dis... Acute Leukemia ... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Myelodysplastic... Mantle Cell Lym... Follicular Lymp... Diffuse Large B... Non Hodgkin Lym... Graft Vs Host D... Graft-versus-ho... | Vorinostat Blood and Marro... Tacrolimus (or ... Methotrexate Mycophenolate M... Cyclophosphamid... | 3 Years - 39 Years | University of Michigan Rogel Cancer Center | |
| Combination Chemotherapy or Observation Following Surgery in Treating Infants With Neuroblastoma | NCT00002803 | Neuroblastoma | cyclophosphamid... doxorubicin hyd... vincristine sul... conventional su... | - 1 Year | National Cancer Institute (NCI) | |
| Radiation Therapy Plus Combination Chemotherapy In Treating Patients With Limited Stage Small Cell Lung Cancer | NCT00003364 | Lung Cancer | cisplatin cyclophosphamid... doxorubicin hyd... etoposide vincristine sul... radiation thera... | - 74 Years | National Cancer Institute (NCI) | |
| E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C | NCT03623750 | Carcinoma, Non-... | EGFR-TK Inhibit... EGF-PTI Cyclophosphamid... | 18 Years - | Instituto Oncológico Dr Rosell | |
| Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma | NCT00070447 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... yttrium Y 90 ib... | 18 Years - | National Cancer Institute (NCI) | |
| ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) | NCT06415487 | Locally Advance... Metastatic Soli... | Cyclophosphamid... Fludarabine ACE2016 Pembrolizumab | 18 Years - | Acepodia Biotech, Inc. | |
| Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma | NCT03719105 | NK-Cell Lymphom... NK-Cell Leukemi... Peripheral T Ce... | Methotrexate pralatraxate, Ifosfamide Dexamethasone Etoposide calaspargase pe... cyclophosphamid... Doxorubicin Prednisone Brentuximab Ved... | 1 Year - 31 Years | New York Medical College | |
| Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer | NCT00431080 | Breast Cancer | Docetaxel Paclitaxel Epirubicin Cyclophosphamid... 5-fluoruracil Granulocyte-col... | 18 Years - 75 Years | Hellenic Oncology Research Group | |
| Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia | NCT00040690 | Leukemia Lymphoma | filgrastim cyclophosphamid... cytarabine doxorubicin hyd... etoposide ifosfamide leucovorin calc... methotrexate vincristine sul... radiation thera... | 16 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma | NCT00026208 | Lymphoma, Hodgk... Lymphoma Hodgkin Disease Lymphoma: Hodgk... | Vincristine Cyclophosphamid... Doxorubicin Prednisone Bleomycin Etoposide Low-dose radiot... | 18 Years - 70 Years | Stanford University | |
| Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | NCT05106296 | Ependymoma Medulloblastoma Glioblastoma Primary Brain T... | Ibrutinib Indoximod Cyclophosphamid... Etoposide | 12 Years - 25 Years | Augusta University | |
| An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | NCT06047080 | Large B-Cell Ly... | Glofitamab Polatuzumab ved... Rituximab Cyclophosphamid... Doxorubicin Prednisone | 18 Years - 80 Years | Hoffmann-La Roche | |
| RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor | NCT03536039 | Lymphoma, Large... | NGR-hTNF RITUXIMAB Doxorubicin Cyclophosphamid... Vincristine Prednisone | 18 Years - 80 Years | IRCCS San Raffaele | |
| TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer | NCT03287674 | Metastatic Ovar... | Cyclophosphamid... Fludarabine TIL infusion Interleukin-2 Ipilimumab Nivolumab | 18 Years - 70 Years | Herlev Hospital | |
| A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma | NCT01569750 | CD20-positive B... | Part 1, Cohort ... Part 1, Cohort ... Part 1, Cohort ... Part 2, Cohort ... Part 2, Cohort ... | 18 Years - | Janssen Research & Development, LLC | |
| Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis | NCT03252600 | Recurrent Prima... | Cyclophosphamid... Dexamethasone Elotuzumab Laboratory Biom... Lenalidomide Pharmacological... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma | NCT02425306 | Melanoma | 6MHP Montanide ISA-5... polyICLC Cyclophosphamid... | 18 Years - | University of Virginia | |
| Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease | NCT00004010 | Lymphoma | bleomycin sulfa... filgrastim ABVD regimen cyclophosphamid... dacarbazine doxorubicin hyd... etoposide prednisone procarbazine hy... vinblastine sul... vincristine sul... radiation thera... | - 21 Years | Children's Oncology Group | |
| Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes | NCT00007904 | Breast Cancer | filgrastim cyclophosphamid... doxorubicin hyd... paclitaxel tamoxifen citra... adjuvant therap... radiation thera... | 18 Years - | Case Comprehensive Cancer Center | |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | NCT00723099 | Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Myeloge... Chronic Phase C... Indolent Non-Ho... Lymphoma Mixed Phenotype... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Plasm... Recurrent Small... Recurrent T-Cel... Refractory Chro... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Lymp... Refractory Mant... Refractory Smal... T-Cell Non-Hodg... | Allogeneic Hema... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ... | - 69 Years | Fred Hutchinson Cancer Center | |
| Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy | NCT00960115 | Non-small Cell ... | Tecemotide (L-B... Single low dose... Placebo Saline | 20 Years - | Merck KGaA, Darmstadt, Germany | |
| Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma | NCT00055640 | Lymphoma | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... microarray anal... | 18 Years - | Case Comprehensive Cancer Center | |
| CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors | NCT02757391 | Colorectal Aden... Metastatic Chol... Metastatic Colo... Metastatic Dige... Metastatic Esop... Metastatic Gast... Metastatic Panc... Stage IV Colore... Stage IV Esopha... Stage IV Gastri... Stage IV Pancre... Stage IVA Color... Stage IVB Color... | Adoptive Immuno... Aldesleukin Cyclophosphamid... Laboratory Biom... Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma | NCT01451515 | Lymphoblastic L... | Prednisone Vincristine Daunorubicin PEG-asparaginas... Erwinia asparag... Doxorubicin Cyclophosphamid... Cytarabine Thioguanine Clofarabine Methotrexate Mercaptopurine Dexamethasone Hydrocortisone Etoposide | - 21 Years | St. Jude Children's Research Hospital | |
| Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects | NCT01516307 | Metastatic Brea... | OPT-822/OPT-821... Phosphate Buffe... Cyclophosphamid... | 21 Years - | OBI Pharma, Inc | |
| STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS | NCT02586038 | Multiple Myelom... | MLN9708 Dexamethasone Cyclophosphamid... Thalidomide | 65 Years - | University of Turin, Italy | |
| Adoptive Therapy Using Antigen-Specific CD4 T-Cells | NCT02210104 | Melanoma Sarcoma | Ipilimumab Cyclophosphamid... CD4+ T cells | 18 Years - | M.D. Anderson Cancer Center | |
| Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) | NCT06210750 | T Acute Lymphob... T Lymphoblastic... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Calaspargase Pe... Computed Tomogr... Cyclophosphamid... Cytarabine Daunorubicin Dexamethasone Doxorubicin Echocardiograph... Lumbar Puncture Mercaptopurine Methotrexate Multigated Acqu... Navitoclax Nelarabine Pegaspargase Positron Emissi... Thioguanine Venetoclax Vincristine X-Ray Imaging | 18 Years - 60 Years | National Cancer Institute (NCI) | |
| Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma | NCT01569204 | Hodgkin Lymphom... | Etoposide Cyclophosphamid... Doxorubicin Prednisone Procarbazine Dexamethasone Dacarbazine Brentuximab Ved... | 18 Years - 60 Years | University of Cologne | |
| Optimizing PTCy Dose and Timing | NCT03983850 | Graft Versus Ho... Hematologic Neo... | Busulfan Fludarabine Cyclophosphamid... Mycophenolate M... Sirolimus | 12 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma | NCT02062359 | Metastatic Canc... Metastatic Mela... | Anti-NY ESO-1 T... Aldesleukin Cyclophosphamid... Fludarabine | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia | NCT00002785 | Leukemia | filgrastim asparaginase cyclophosphamid... cyclosporine cytarabine daunorubicin hy... dexamethasone etoposide leucovorin calc... mercaptopurine mesna methotrexate methylprednisol... pegaspargase prednisone therapeutic hyd... vincristine sul... allogeneic bone... low-LET cobalt-... low-LET photon ... | - 1 Year | Children's Oncology Group | |
| Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer | NCT02593227 | Breast Cancer | Low dose FRα va... Cyclophosphamid... High dose FRα v... | 18 Years - | Marker Therapeutics, Inc. | |
| Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia | NCT00049569 | L1 Childhood Ac... L2 Childhood Ac... Non-T, Non-B Ch... Recurrent Child... T-cell Childhoo... | cytarabine methotrexate vincristine sul... prednisone pegaspargase doxorubicin hyd... imatinib mesyla... cyclophosphamid... etoposide filgrastim leucovorin calc... asparaginase therapeutic hyd... | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| Molecular Triaging of Newly Diagnosed Breast Cancer | NCT01159236 | Breast Cancer | Paclitaxel Fluorouracil Doxorubicin Epirubicin Cyclophosphamid... Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer | NCT00093795 | Breast Cancer | Cyclophosphamid... Docetaxel Gemcitabine Paclitaxel Doxorubicin | 18 Years - | NSABP Foundation Inc | |
| Combination Chemotherapy in Treating Children With Neuroblastoma | NCT00003093 | Neuroblastoma | filgrastim sargramostim carboplatin cyclophosphamid... doxorubicin hyd... etoposide conventional su... neoadjuvant the... | - 20 Years | Children's Oncology Group | |
| Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma | NCT02298348 | Neuroblastoma | Sorafenib Cyclophosphamid... Topotecan | - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Treatment With Pazopanib for Neoadjuvant Breast Cancer | NCT00849472 | Neoplasms, Brea... | doxorubicin + c... paclitaxel + pa... surgery pazopanib monot... | 18 Years - | GlaxoSmithKline | |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | NCT01814046 | Metastatic Ocul... Metastatic Uvea... | Aldesleukin Cyclophosphamid... Fludarabine Young Tumor Inf... | 16 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma | NCT02425306 | Melanoma | 6MHP Montanide ISA-5... polyICLC Cyclophosphamid... | 18 Years - | University of Virginia | |
| Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma | NCT00072280 | Sarcoma | dactinomycin cyclophosphamid... etoposide ifosfamide vincristine sul... Conventional Su... MESNA (mercapto... Filgrastim | - 2 Years | Children's Oncology Group | |
| Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer | NCT00546377 | Leukemia Lymphoma | filgrastim pegfilgrastim rituximab sargramostim cyclophosphamid... mitoxantrone hy... pentostatin fluorescence in... gene rearrangem... polymerase chai... protein express... flow cytometry biopsy | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma | NCT00144807 | Diffuse Large C... | rituximab doxorubicin cyclophosphamid... autologous stem... | 18 Years - 59 Years | Lymphoma Study Association | |
| Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT01527149 | Stage I Mantle ... Stage II Contig... Stage II Non-Co... Stage III Mantl... Stage IV Mantle... | Autologous Hema... Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Laboratory Biom... Methotrexate Ofatumumab Vincristine Sul... | 18 Years - 70 Years | Roswell Park Cancer Institute | |
| Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia | NCT04789408 | Acute Myeloid L... | Cyclophosphamid... Fludarabine KITE-222 | 18 Years - | Gilead Sciences | |
| Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia | NCT01677949 | Acute Myeloid L... Acute Lymphobla... | Clofarabine Etoposide Cyclophosphamid... allogeneic hema... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer | NCT00001426 | Ovarian Neoplas... | Cyclophosphamid... Paclitaxel Cisplatin G-CSF | - | National Institutes of Health Clinical Center (CC) | |
| Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia | NCT00613457 | Leukemia | dexamethasone asparaginase Asparaginase cyclophosphamid... cytarabine daunorubicin doxorubicin Etoposide Ifosfamide mercaptopurine Methotrexate prednisone thioguanine Vincristine Vindesine | 1 Year - 17 Years | Associazione Italiana Ematologia Oncologia Pediatrica | |
| Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia | NCT05453500 | B Acute Lymphob... | Bone Marrow Asp... Cyclophosphamid... Doxorubicin Etoposide Prednisone Rituximab Tafasitamab Vincristine | 18 Years - | University of Washington | |
| Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia | NCT04881240 | Acute Lymphobla... Acute Lymphobla... Pediatric ALL | CD19-CAR(Mem) T... Cyclophosphamid... Fludarabine Mesna CliniMACS Leukapheresis | - 21 Years | St. Jude Children's Research Hospital | |
| Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma | NCT03731832 | Refractory Mult... | MLN9708 Pomalidomide 4 ... Dexamethasone Cyclophosphamid... | 18 Years - | GWT-TUD GmbH | |
| R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL | NCT01148446 | Elderly Patient... Diffuse Large B... | Cyclophosphamid... Cyclophosphamid... Doxorubicin Vincristine Prednisone Prednisone Epirubicin Vinblastine Rituximab G-CSF | 66 Years - 80 Years | Fondazione Italiana Linfomi - ETS |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
